Development of antitumor immune responses in reconstituted lymphopenic hosts.
about
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and ImmunotherapyAdoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cellsHeat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Homeostatic proliferation is a barrier to transplantation tolerance.In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hostsDisruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity.Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samplesSelective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.Making room for T cellsTumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.Chemotherapy and tumor immunity: an unexpected collaborationCancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regressionCombination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Innate and virtual memory T cells in man.Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.Immunotherapy of malignant brain tumors.In vivo survival and homeostatic proliferation of natural killer cells.Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipientsInterleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceAntigen loss and tumor-mediated immunosuppression facilitate tumor recurrenceTransient T cell depletion causes regression of melanoma metastases.The anticancer immune response: indispensable for therapeutic success?Immune system derived from homeostatic proliferation generates normal CD8 T-cell memory but altered repertoires and diminished heterologous immune responses.MHC-dependent desensitization of intrinsic anti-self reactivity.Negative regulators in homeostasis of naïve peripheral T cells.In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation.Toward effective immunotherapy for the treatment of malignant brain tumors
P2860
Q24798754-CC53F415-3A89-4C32-A5DC-A3C583004C1BQ24802970-3672F715-25B5-4A44-AD68-8F46F6B0D087Q33585305-E8A5597A-8DBE-4742-9A91-CC08DDDB5F4BQ33710973-8C353B92-2EB7-483B-BDB6-ADE296FB2952Q33724352-D5865528-5E30-41F6-993A-2CD9141E083AQ33731951-5F305C33-482F-451D-B6DD-13E9A2572C4DQ33756565-1E269E91-FAEE-4918-974E-D68BB7783825Q33772479-90B57F17-381F-43BC-882F-288B0348DFF2Q33772507-EC544DD4-0175-4EBB-8471-B236A716D1F0Q33801059-20446A6C-1393-4D3B-A7E8-8CF1F4A4A8EFQ34634616-37CE2964-BF3F-475D-94D5-1416E0CAA834Q34657644-DB01C70A-607D-453A-BE73-5CD60B8AACB1Q34657700-E1D4C095-802A-46D2-A7C1-0B5B12FCBD83Q34744971-20F6B5A4-A80A-4726-9320-7E16D8B0506AQ34823085-17946488-913D-482E-91EB-FA009C88D17EQ34909777-223F6883-0988-4496-B494-A8A4F2926D58Q35033249-92139460-1E79-481D-85FF-DA5363487608Q35049773-AE0F3606-0CD5-4C98-9F78-405EA694309EQ35146131-44936C3D-E022-4E46-8A95-5BAA251FCBEDQ35203752-3F2E523C-1E0E-41F6-BF20-8ED520CE84BBQ35594089-57F97919-2C41-4BC0-B932-7926AAF2729DQ35966890-FD546C23-5EF0-4926-871A-A415424DCDFFQ36062926-80441F34-BE63-4E5C-A989-E36F1946DE18Q36162929-EA5EB464-CB44-41DB-B602-FDE26B61EA90Q36370683-7E845FD8-0F8F-45ED-B3F3-D3AEA606E328Q36422292-DD2EFBF3-97BC-4001-BD4F-1E09C0B5E8CBQ36451574-42D14DEE-BBB6-4433-BD05-53D590717C36Q36456753-ACB2C53C-9D7E-4B5C-B6AD-FE734D01BAC1Q36482614-0521144F-D881-43B9-802C-515F8D828F71Q36555546-E2AD2BE7-AA49-4C8D-A19C-FDB19659B83FQ36570359-43495BCD-FFF0-4D35-A2B5-3231F3BB60C1Q36580176-56CBA57C-98B0-426D-A387-D8EBC67B8748Q36677608-D62F8850-A628-4684-9BC5-608B29E2F299Q36787568-CBA4FEF5-4D40-4BA9-BAE4-B79680E098AEQ36978119-5EA346B2-3093-43D0-845E-8ED54B16A5C3Q36983409-E5EF571E-0132-4E69-828B-FB2DEB3C6890Q37086932-EC6535F6-4778-44D6-A69A-92E52F549D49Q37442739-BB3B3AD6-839E-4352-AEBC-065F07B330E4Q37482548-3677EF3B-65FF-4488-B89A-E9C99CDC1845Q37533657-359B54FB-637A-45C9-9B64-E87D924A2D3D
P2860
Development of antitumor immune responses in reconstituted lymphopenic hosts.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@en
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@nl
type
label
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@en
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@nl
prefLabel
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@en
Development of antitumor immune responses in reconstituted lymphopenic hosts.
@nl
P2093
P1433
P1476
Development of antitumor immune responses in reconstituted lymphopenic hosts
@en
P2093
Bernard A Fox
Christian H Poehlein
Hong-Ming Hu
Walter J Urba
P304
P407
P577
2002-07-01T00:00:00Z